Log In
BCIQ
Print this Print this
 

M2SR, RedeeFlu

  Manage Alerts
Collapse Summary General Information
Company FluGen Inc.
DescriptionReplication-deficient live attenuated vaccine based on the deletion of the influenza A virus matrix protein 2 (M2) gene
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationInfluenza virus
Indication DetailsVaccinate against H5N1 avian influenza virus infection; Vaccinate against influenza virus infection
Regulatory Designation
PartnerArecor Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/05/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today